LNA043
Showing 1 - 6 of 6
Osteoarthritis, Knee Trial in Shinjuku-ku, Osaka (LNA043, Placebo)
Completed
- Osteoarthritis
- Knee
- LNA043
- Placebo
-
Shinjuku-ku, Tokyo, Japan
- +1 more
Aug 8, 2022
Wounds and Injuries Trial in Czechia, Denmark, United States (LNA043, Placebo)
Completed
- Wounds and Injuries
- LNA043
- Placebo
-
Phoenix, Arizona
- +18 more
Jan 24, 2023
Knee Osteoarthritis Trial in Worldwide (canakinumab, LNA043, Placebo to canakinumab)
Recruiting
- Knee Osteoarthritis
- canakinumab
- +2 more
-
Clearwater, Florida
- +19 more
Dec 14, 2022
Knee Cartilage Lesion Trial in Wien (LNA043, to LNA043)
Terminated
- Knee Cartilage Lesion
- LNA043
- placebo to LNA043
-
Wien, Austria
- +1 more
Oct 6, 2021
Osteoarthritis Trial in Worldwide (LNA043 Dosing Regimen A, LNA043 Dosing Regimen B, LNA043 Dosing Regimen C)
Recruiting
- Osteoarthritis
- LNA043 Dosing Regimen A
- +4 more
-
Phoenix, Arizona
- +107 more
Nov 4, 2022
Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery Trial in Phoenix (LNA043, Placebo)
Completed
- Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
- LNA043
- Placebo
-
Phoenix, ArizonaNovartis Investigative Site
Dec 9, 2020